291 related articles for article (PubMed ID: 33707442)
1. An extended APOBEC3A mutation signature in cancer.
Langenbucher A; Bowen D; Sakhtemani R; Bournique E; Wise JF; Zou L; Bhagwat AS; Buisson R; Lawrence MS
Nat Commun; 2021 Mar; 12(1):1602. PubMed ID: 33707442
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3A is a prominent cytidine deaminase in breast cancer.
Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
[TBL] [Abstract][Full Text] [Related]
3. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
[TBL] [Abstract][Full Text] [Related]
4. Single-stranded DNA binding proteins influence APOBEC3A substrate preference.
Brown AL; Collins CD; Thompson S; Coxon M; Mertz TM; Roberts SA
Sci Rep; 2021 Oct; 11(1):21008. PubMed ID: 34697369
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
6. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
Nat Commun; 2024 Mar; 15(1):2369. PubMed ID: 38499553
[TBL] [Abstract][Full Text] [Related]
8. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.
Buisson R; Langenbucher A; Bowen D; Kwan EE; Benes CH; Zou L; Lawrence MS
Science; 2019 Jun; 364(6447):. PubMed ID: 31249028
[TBL] [Abstract][Full Text] [Related]
9. A DNA sequence recognition loop on APOBEC3A controls substrate specificity.
Logue EC; Bloch N; Dhuey E; Zhang R; Cao P; Herate C; Chauveau L; Hubbard SR; Landau NR
PLoS One; 2014; 9(5):e97062. PubMed ID: 24827831
[TBL] [Abstract][Full Text] [Related]
10. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
Caval V; Suspène R; Shapira M; Vartanian JP; Wain-Hobson S
Nat Commun; 2014 Oct; 5():5129. PubMed ID: 25298230
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
[TBL] [Abstract][Full Text] [Related]
12. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
13. Learning mutational signatures and their multidimensional genomic properties with TensorSignatures.
Vöhringer H; Hoeck AV; Cuppen E; Gerstung M
Nat Commun; 2021 Jun; 12(1):3628. PubMed ID: 34131135
[TBL] [Abstract][Full Text] [Related]
14. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
15. Genetic inhibitors of APOBEC3B-induced mutagenesis.
Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
[TBL] [Abstract][Full Text] [Related]
16. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes.
Sanchez A; Ortega P; Sakhtemani R; Manjunath L; Oh S; Bournique E; Becker A; Kim K; Durfee C; Temiz NA; Chen XS; Harris RS; Lawrence MS; Buisson R
Nat Commun; 2024 Mar; 15(1):2370. PubMed ID: 38499542
[TBL] [Abstract][Full Text] [Related]
17. Monitoring APOBEC3A protein levels in human cancer cells.
Dananberg A; Maciejowski J
Methods Cell Biol; 2024; 182():313-327. PubMed ID: 38359985
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.
Hoopes JI; Cortez LM; Mertz TM; Malc EP; Mieczkowski PA; Roberts SA
Cell Rep; 2016 Feb; 14(6):1273-1282. PubMed ID: 26832400
[TBL] [Abstract][Full Text] [Related]
19. Creating RNA Specific C-to-U Editase from APOBEC3A by Separation of Its Activities on DNA and RNA Substrates.
Tang G; Xie B; Hong X; Qin H; Wang J; Huang H; Hao P; Li X
ACS Synth Biol; 2021 May; 10(5):1106-1115. PubMed ID: 33938211
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the Enzyme-Substrate Properties for APOBEC3A-Mediated RNA Editing.
Kim K; Shi AB; Kelley K; Chen XS
J Mol Biol; 2023 Sep; 435(17):168198. PubMed ID: 37442413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
